Search results for "Fdg pet ct"

showing 5 items of 5 documents

Impact of molecular and histological subtype of breast cancer on 18FDG-PET/CT imaging: Knowledge gained from recent studies

2016

International audience; Over the past few years, several studies have focused attention on the impact of breast cancer (BC) histological subtype or BC phenotype, as defined by hormone receptors (HR) and HER2 status, on the results of FDG-PET/CT at staging, or during neoadjuvant chemotherapy (NAC). At staging, sclerotic bone metastases from invasive lobular carcinoma (ILC) demonstrated low or no FDG uptake in comparison to metastases from invasive ductal carcinoma (IDC). The CT component of PET/CT imaging should be carefully analyzed in the staging of ILC. In patients with triple negative or HER2-positive tumors, the proportion of extraskeletal metastases is high; this must be taken into acc…

Oncologymedicine.medical_specialtyPathologyStagingPET/CTmedicine.medical_treatmentBiophysicsEstrogen receptorER-positive breast cancerNeoadjuvant chemotherapy030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerTriple-negative breast cancerResponse assessmentInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMedicineRadiology Nuclear Medicine and imagingskin and connective tissue diseasesHER2-positive breast cancerTriple-negative breast cancerChemotherapyPET-CTPathological complete responseRadiological and Ultrasound Technologybusiness.industrymedicine.disease18fdg pet ctPrognosis3. Good healthHormone receptor030220 oncology & carcinogenesisInvasive lobular carcinoma(18)FDGbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

A xanthogranulomatous process resembling residual disease on endof- treatment 18f-FDG-PET/CT and Whole Body Magnetic Resonance performed on a primary…

2016

We report the case of a woman, affected by breast diffuse large B-Cell lymphoma, who developed a xanthogranulomatous process wrongly interpreted as residual disease on 18F-FDG-PET/CTand Whole Body Magnetic Resonance after treatment with ibrutinib plus standard immunochemotherapy. Newer drugs, such as immunomodulatory agents and checkpoint inhibitors, have demonstrated high effectiveness on lymphoma, but are associated with unclear imaging features such as tumor flare or pseudo-progression, related to inflammatory reactions. Wide imaging techniques availability improves diagnostic possibilities. However, the awareness of the adopted treatment strategy and its possible implications on imaging…

Pathologymedicine.medical_specialtyWhole body magnetic rcsonanccmedicine.diagnostic_testbusiness.industryIbrutinibObstetrics and GynecologyMagnetic resonance imagingCHOPFDG-PET/CTBrcasr lymphoma; FDG-PET/CT; Ibrutinib; Rituximab; Whole body magnetic rcsonancc; Xantogranulomatous process; Obstetrics and GynecologyPrimary Breast Lymphomachemistry.chemical_compoundchemistryXantogranulomatous proceIbrutinibmedicineFdg pet ctRituximabRituximabWhole bodybusinessNuclear medicineBrcasr lymphomamedicine.drugGiornale Italiano di ostetricia e ginecologia
researchProduct

The role of 18F-FDG PET/CT in early infectious discitis: a case report after a negative MRI

2019

We present the case of a 70 years old woman with infectious discitis which was detected using Fluorine fluodeoxiglucose positron emission tomography/computed tomography (18F-FDG PET/CT), after a negative magnetic resonance imaging. A Streptococuss gallolyticus (bovis gender bacteria) grow on culture. In addition 18F-FDG PET also demonstrated infectious endocarditis which was confirmed by transesophageal echocardiography and a colonic neoplasm. Here we have highlighted the potential role of 18F-FDG PET/CT study in patients with a clinical history suggestive of infectious discitis with a negative or indifferent magnetic resonance imaging. Keywords: 18F-FDG PET/TC, Spondylodiscitis, Pyogenic v…

lcsh:Medical physics. Medical radiology. Nuclear medicineSpondylodiscitismedicine.medical_specialtylcsh:R895-920030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicineEndocarditisRadiology Nuclear Medicine and imagingIn patientmedicine.diagnostic_testbiology18F-FDG PET/TCbusiness.industrySpondylodiscitisMagnetic resonance imagingPyogenic vertebral osteomyelitismedicine.diseaseStreptococcus bovisbiology.organism_classificationStreptococcus bovisPositron emission tomographyDiscitisFdg pet ctRadiologyNuclear Medicinebusiness030217 neurology & neurosurgeryRadiology Case Reports
researchProduct

Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by 18F-FDG-PET/CT

2018

Objective:To investigate metabolic parameters as predictive of local response after stereotactic body radiation therapy (SBRT) for liver-oligometastases.Methods:Inclusion criteria of the present re...

medicine.medical_specialtyStereotactic body radiation therapybusiness.industryLiver NeoplasmsHumans; Liver Neoplasms; Retrospective Studies; Treatment Outcome; Fluorodeoxyglucose F18; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiosurgery; Radiology Nuclear Medicine and ImagingGeneral MedicineRadiosurgery030218 nuclear medicine & medical imaging03 medical and health sciencesTreatment Outcome0302 clinical medicineFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyNuclear Medicine and Imaging030220 oncology & carcinogenesisHumansMedicineRadiology Nuclear Medicine and imagingFdg pet ctRadiologyRadiopharmaceuticalsRadiologybusinessRetrospective StudiesThe British Journal of Radiology
researchProduct

Prognostic Value of Radiomics Signature By Diagnostic 18F-FDG PET/CT Analysis in Aggressive Non-Hodgkin's Lymphoma

2018

Abstract BACKGROUND Although the overall prognosis of patients with aggressive non-Hodgkin's lymphoma (NHL) has improved, nearly a third of patients will have refractory disease or relapse. Identification of these high-risk patients using traditional prognostic factors is limited. PET is the recommended imaging modality for the staging of FDG-avid lymphoma but the value of a comprehensive new imaging biomarkers analysis applied to PET for the prediction of patients outcome has still not been deeply investigated. New metrics estimating the overall tumor burden such as metabolic tumor volume (MTV) and those that may capture intratumoral biological heterogeneity such as total lesion glycolysis…

medicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologyMetabolic tumor volumemedicine.diseaseLinear discriminant analysisBiochemistryLymphomaNon-Hodgkin's lymphomaCorrelationRadiomicsKurtosisMedicineFdg pet ctRadiologybusinessBlood
researchProduct